Itepekimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD). According to Globaldata, it is involved in 14 clinical trials, of which 6 were completed, 4 are ongoing, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Itepekimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Itepekimab is expected to reach an annual total of $220 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Itepekimab Overview

Itepekimab is under development for the treatment of chronic obstructive pulmonary disease. It is administered intravenously and subcutaneously. The drug candidate is a fully human monoclonal antibody which acts by targeting the interleukin-33 (IL-33). The drug candidate is a new molecular entity developed based on VelocImmune technology. The drug candidate was also under development for the treatment of atopic dermatitis and asthma.

Regeneron Pharmaceuticals Overview

Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

The company reported revenues of (US Dollars) US$12,172.9 million for the fiscal year ended December 2022 (FY2022), a decrease of 24.3% over FY2021. The operating profit of the company was US$4,738.9 million in FY2022, compared to an operating profit of US$8,946.8 million in FY2021. The net profit of the company was US$4,338.4 million in FY2022, compared to a net profit of US$8,075.3 million in FY2021.

For a complete picture of Itepekimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.